Table 1.

Demographics and performance status

Radiotherapy only (n = 286)Radiotherapy + temozolomide (n = 287)
Sex (%)
    Female109 (38)103 (36)
    Male175 (61)185 (64)
    Missing1 (<1)0
Age (y)
    Median56.055.0
    Range23-7018-70
Age (%)
    18-<50 y81 (28)90 (31)
    50-<65 y163 (57)156 (54)
    65 y or older41 (14)42 (15)
Histology (%)
    Central pathology review
        Eligible228 (80)222 (77)
            Glioblastoma multiforme200 (70)188 (65)
            Glioblastoma multiforme (giant cell)2 (1)4 (1)
            Glioblastoma multiforme (with oligodendroma component)25 (9)27 (9)
            Glioblastoma multiforme (gliosarcoma)1 (<1)3 (1)
        Ineligible11 (4)13 (5)
No central pathology review46 (16)53 (18)
Type of surgery (%)
    Brain biopsy only46 (16)47 (17)
    Brain debulking (partial resection)126 (44)125 (43)
    Brain debulking (total resection)113 (40)116 (40)
Weeks from surgery to randomization
    Subjects with biopsy only (%)46 (16)47 (16)
        Median (wk)4.03.4
        Range (wk)1.9-6.01.1-5.9
    Subjects with debulking (%)239 (84)241 (84)
        Median (wk)4.14.3
        Range (wk)0.0-6.11.0-6.0
WHO performance status (%)
    0112 (39)116 (40)
    1139 (49)136 (47)
    234 (12)36 (13)
Mini-mental status evaluation (%)273 (96)278 (97)
    Median score29.029.0
    Number of subjects per range (%)
        0-114 (1)4 (1)
        12-28121 (42)125 (43)
        29-30148 (52)149 (52)
        Missing12 (4)10 (3)
Corticosteroids at randomization (%)214 (75)194 (67)